Latest News and Press Releases

-- Company builds out management team and continues to implement its clinical programs to advance much-needed technologies for women’s health -- ATLANTA, March 24, 2022 (GLOBE NEWSWIRE) -- Femasys...

-- Seasoned financial executive with 25 years of experience leading public and private biotech companies throughout various stages -- ATLANTA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Femasys Inc....

ATLANTA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally...

ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally...

-- Up to 792-patient, pivotal LOCAL trial progressing for FemaSeed® after receipt of investigational device exemption (IDE) submission approval -- -- Femasys added to the Russell...

ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include...

ATLANTA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women’s healthcare...

-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:...

Completed initial public offering (“IPO”) raising net proceeds of $31.6 millionAppointed Anne Morrissey to the Board of Directors, an industry expert with decades of medical device experienceInitiated...

First in Class Insemination Treatment for Infertility LOCAL Pivotal Trial to Enroll Up to 792 Patients Across 20 U.S. Centers ATLANTA, July 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:...